Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Tratamiento Personalizado del Tabaquismo en Atención Primaria

2 de noviembre de 2026 actualizado por: Washington University School of Medicine

Una intervención multinivel para personalizar y mejorar el tratamiento del tabaquismo en atención primaria

This study examines the application of precision treatment intervention for smoking cessation from both the clinician perspective and patient perspective, and compares it to usual care on tobacco treatment in the primary care setting. The precision treatment intervention includes personalized tobacco treatment recommendations using the patient's clinical, genetic, and biomarker information. This approach may increase effectiveness and adherence for the patient, and increase the clinician's likelihood of prescribing.

Descripción general del estudio

Estado

Reclutamiento

Descripción detallada

The overarching goal of this study is to test the impact of a multilevel precision treatment intervention aiming to address gaps in clinician and patient uptake of tobacco treatment and overall treatment effectiveness. This study builds on evidence that (1) genetic and metabolic factors may inform precision tobacco treatment and (2) increasingly high demand for precision treatment, in particular, may signal its potential to activate behavior change. The multilevel precision treatment intervention to be tested--PrecisionTx-- provides the opportunity to present personalized risk, benefit, and treatment recommendation to increase clinician ordering, patient uptake, and overall effectiveness of tobacco treatment. This study aims to understand the relative benefit of precision treatment over usual care and associated mechanistic and implementation outcomes. Therefore, the investigators propose a 2-arm cluster randomized controlled trial of 50 clinicians and 800 screen-eligible patients (~16 per clinician) from diverse primary care settings. Clinicians and patients will be randomized with 1:1 allocation to usual care (UC) vs. precision treatment (PT) to evaluate the effect of precision treatment on smoking cessation success. In Aim 1, the investigators will test the effect of PT on clinician prescribing (or patient receipt of medication when prescription is not needed) and patient use of medication for smoking cessation. The investigators hypothesize that patient receipt of tobacco treatment medication for smoking cessation at 6 months post-intervention will be higher in PT vs UC. The investigators also hypothesize that patient use of cessation medication at 6 months post-intervention will be higher in PT vs. UC. In Aim 2, the investigators will test the effect of PT on patient smoking abstinence. The investigators hypothesize that patient bioverified smoking abstinence at 6 months will be higher in PT vs. UC. In Aim 3, the investigators will examine mechanisms of behavior change and implementation outcomes. The investigators will evaluate putative mechanisms for PT (e.g., outcome expectancy and withdrawal suppression). The investigators will conduct assessments at baseline, intervention, and 1-month, 3-month, 6-month, and 12-month post-intervention follow-ups.

Primary outcomes include patient receipt of tobacco treatment, patient use of tobacco treatment, and patient smoking abstinence. Secondary outcomes include patient receipt of recommended medication, patient medication adherence, and additional patient smoking cessation outcomes. Mechanistic outcomes include clinician level (perceived benefit, outcome expectancy), clinician-patient interaction (self-efficacy), patient-level (perceived risk, outcome expectancy, withdrawal suppression, adverse events). Implementation outcomes will be evaluated based on the RE-AIM framework. The study is an innovative paradigm shift from a traditional treatment model to precision treatment that includes both metabolic and genetic markers to motivate and guide tobacco treatment for both clinicians and patients, integrated within primary care.

Smoking is a leading cause of premature death, causing more than half of all cancer deaths. However, tobacco treatment is often not provided and is not highly effective in primary care. New evidence suggests that a precision treatment approach to motivate and guide treatment based on personal genetic and metabolic markers could improve treatment uptake and quit success. This study will test the impact of a multilevel precision treatment intervention on improving tobacco treatment and health outcomes in primary care.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

850

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Li-Shiun Chen, ScD, MD, MPH
  • Número de teléfono: 314-362-3932
  • Correo electrónico: li-shiun@wustl.edu

Copia de seguridad de contactos de estudio

  • Nombre: Alex Ramsey, PhD
  • Número de teléfono: 314-362-5370
  • Correo electrónico: aramsey@wustl.edu

Ubicaciones de estudio

    • Missouri
      • St Louis, Missouri, Estados Unidos, 63110
        • Reclutamiento
        • Washington University School of Medicine
        • Contacto:
          • Li-Shiun Chen, ScD, MD, MPH
          • Número de teléfono: 314-362-3932
          • Correo electrónico: li-shiun@wustl.edu
        • Contacto:
          • Alex Ramsey, PhD
          • Número de teléfono: 314-362-5370
          • Correo electrónico: aramsey@wustl.edu
        • Investigador principal:
          • Li-Shiun Chen, ScD, MD, MPH
        • Investigador principal:
          • Alex Ramsey, PhD
        • Sub-Investigador:
          • Laura Bierut, MD
        • Sub-Investigador:
          • Esther Lu, PhD
        • Sub-Investigador:
          • Robert Schnoll, PhD
        • Sub-Investigador:
          • Timothy Baker, PhD
        • Sub-Investigador:
          • Hilary Tindle, MD
        • Sub-Investigador:
          • Rachel Tyndale, PhD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Eligibility Criteria for Primary and Specialty Care Clinicians

  • Clinician from participating clinic
  • At least 18 years of age
  • Can speak and understand English

Eligibility Criteria for Primary Care and Specialty Patients

Inclusion:

  • Patient at participating clinic
  • Age 18 years or older, inclusive
  • Current smoking (cigarettes per day >=5)
  • Can speak and understand English
  • Willing to consider medication to help reduce craving or smoking such as nicotine patch, lozenge, or varenicline

Exclusion:

  • Active use of smoking cessation medication (within the past 30 days)
  • Receipt of smoking cessation medication or prescription for smoking cessation medication (within the past 30 days)
  • Having a contraindication for cNRT or varenicline (allergic reactions, current cardiac problems, pregnancy)

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Usual Care

The arm will represent usual care in the primary care clinics. Physicians will receive a report designed to recommend guideline-based tobacco treatment. Patients will receive a report on guideline-based advice about smoking cessation and a brief discussion with a behavior interventionist.

Usual care will be informed by practice guidelines (standard of care, brief advice, and guideline awareness).

Experimental: PrecisionTx

Physicians will receive PrecisionTx, an intervention designed to recommend precision tobacco treatment. Patients will receive PrecisionTx, an intervention designed to recommend precision tobacco treatment, and a brief discussion with a behavior interventionist.

Precision treatment will be informed by practice guidelines (standard of care, brief advice, and guideline awareness), plus patient-specific risk feedback and personalized tobacco treatment recommendations using patients' clinical, genetic, and biomarker information.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Patient receipt of tobacco treatment medication for smoking cessation
Periodo de tiempo: 6 months post-intervention

This will be quantified by the proportion of enrolled patients who receive cessation medication.

6 months post-intervention
Patient use of cessation medication
Periodo de tiempo: 6 months post-intervention

This will be quantified by the proportion of patients taking any cessation medication from time of enrollment through 6 months post-intervention.

6 months post-intervention
Patient smoking abstinence
Periodo de tiempo: 6 months post-intervention

This will be quantified by the proportion of smokers with bioverified point-prevalent abstinence at 6 months.

6 months post-intervention

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Patient receipt of recommended tobacco treatment
Periodo de tiempo: 6 months post-intervention

This will be quantified by the proportion of enrolled patients who received recommended cessation medication.

6 months post-intervention
Patient medication adherence
Periodo de tiempo: 6 months post-intervention

This will be quantified by the proportion of medication taken among medication prescribed.

6 months post-intervention
Patient smoking abstinence among treated
Periodo de tiempo: 6 months post-intervention

This will be quantified by the proportion of smokers with bioverified point-prevalence abstinence among those receiving cessation medication.

6 months post-intervention
Abstinence Outcomes Across Multiple Time Points
Periodo de tiempo: From intervention through 12 months post-intervention

The outcome measures abstinence (self-reported no smoking (not even a puff of a cigarette) for at least 7 days prior to the assessment) over these time points.

From intervention through 12 months post-intervention
Smoking quantity across multiple time points
Periodo de tiempo: From intervention through 12 months post-intervention

The outcome measures smoking quantity (self-reported average cigarettes smoked per day for the past 30 days prior to the assessment) over these time points.

From intervention through 12 months post-intervention
Quit attempts
Periodo de tiempo: 6 and 12 months post-intervention

This outcome measures the number of quit attempts in the past 30 days prior to the assessment over these time points.

6 and 12 months post-intervention

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Perceived benefits (Clinician)
Periodo de tiempo: Exit interview [after clinician has been enrolled in the trial for approximately 6 months]

Clinicians' perceived importance and benefits of patients receiving smoking cessation medications will be assessed using a modified version of the Beliefs and Attitudes About Bupropion Scale.

Exit interview [after clinician has been enrolled in the trial for approximately 6 months]
Outcome expectancies (Clinician)
Periodo de tiempo: Exit interview [after clinician has been enrolled in the trial for approximately 6 months]

Clinicians' outcome expectancies regarding tobacco treatment will be assessed using a modified version of the Stanford Expectation of Treatment Scale.

Exit interview [after clinician has been enrolled in the trial for approximately 6 months]
Self-efficacy regarding patient-clinician interaction (Clinician)
Periodo de tiempo: Exit interview [after clinician has been enrolled in the trial for approximately 6 months]

Clinicians' perceived self-efficacy regarding patient-clinician communication will be assessed using a modified version of the Communication Perceived Self-Efficacy Scale.

Exit interview [after clinician has been enrolled in the trial for approximately 6 months]
Self-efficacy regarding patient-clinician interaction (Patient)
Periodo de tiempo: From intervention through 12 months post-intervention

Patients' perceived self-efficacy regarding patient-clinician communication will be assessed using a modified version of the Communication Perceived Self-Efficacy Scale.

From intervention through 12 months post-intervention
Perceived risk (Patient)
Periodo de tiempo: From baseline through 12 months post-intervention

Patients' perceived smoking-related disease risks will be assessed using a modified version of the Perceived Susceptibility and Severity Scale.

From baseline through 12 months post-intervention
Outcome expectancies (Patient)
Periodo de tiempo: From baseline through 12 months post-intervention

Patients' outcome expectancies regarding tobacco treatment will be assessed using a modified version of the Stanford Expectation of Treatment Scale.

From baseline through 12 months post-intervention
Withdrawal
Periodo de tiempo: From baseline through 12 months post-intervention

Withdrawal severity is assessed by Wisconsin Smoking Withdrawal Scale (WSWS).

From baseline through 12 months post-intervention
Side Effects
Periodo de tiempo: From baseline through 12 months post-intervention

All reported side effects will be summarized and presented for the study. In addition, the investigators will further identify a pre-specified set of key side effects as being related to drug agonist effects (e.g., nausea, vomiting, racing heart, headache, and sleep disturbance). These will be analyzed as the rate of occurrence during the period of cessation medication use, if applicable.

From baseline through 12 months post-intervention

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Li-Shiun Chen, ScD, MD, MPH, Washington University School of Medicine

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

29 de septiembre de 2023

Finalización primaria (Estimado)

31 de marzo de 2028

Finalización del estudio (Estimado)

30 de septiembre de 2028

Fechas de registro del estudio

Enviado por primera vez

21 de abril de 2023

Primero enviado que cumplió con los criterios de control de calidad

4 de mayo de 2023

Publicado por primera vez (Actual)

6 de mayo de 2023

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

3 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • 202205090
  • 1R01DA056050 (Subvención/contrato del NIH de EE. UU.)
  • 5U19CA203654 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

The University will share anonymized human genomic data and relevant associated data from approximately 800 research participants by depositing these data in a NIH-designated data repository or other repositories that meet the appropriate data security measures, confidentiality, privacy, and data use measures. The genotype data will be made available 12 months after trial completion in a NIH-designated data repository after data cleaning and quality control completion, which we anticipate to be in year 5, without restrictions on publication or other dissemination. In addition, information necessary to interpret the submitted data will be included, such as study protocols, data instruments and survey tools.

Marco de tiempo para compartir IPD

12 months after trial completion

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir